<DOC>
	<DOCNO>NCT02411344</DOCNO>
	<brief_summary>The purpose study evaluate activity molecular response endocrine sensitive breast cancer HER2+/HR+ patient treat Pertuzumab-trastuzumab plus Ietrozole .</brief_summary>
	<brief_title>Preoperative Study With Trastuzumab , Pertuzumab Letrozole Patients With Breast Cancer Sensitive Hormonal Therapy</brief_title>
	<detailed_description>The purpose study : - evaluate rate pathologic complete response ( pCR ) , define complete disappearance invasive tumor breast axillary node . - estimate percentage clinical objective response ( cOR ) ( complete plus partial ) breast , assess ultrasonography ( US ) - estimate percentage breast conservative surgery - evaluate safety profile - To perform correlative biomarker analysis</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>primary diagnosis infiltrate breast cancer HR positivity ( ER ≥ 10 % and/or PgR ≥10 % ) HER2 positivity ( IHC 3+ FISH/CISH amplification ) , assess local laboratory . Stage IIIIIA age &gt; 18 yr ECOG Performance Status 01 Postmenopausal status , define least one following : 60 year age ; &lt; 60 year age amenorrheic &gt; /=12 month prior day 1 &lt; 60 year age , without uterus , luteinizing hormone ( LH ) follicle stimulate hormone ( FSH ) value within postmenopausal range Prior bilateral oophorectomy Prior radiation castration amenorrhea least 6 month Cardiac ejection fraction within institutional range normal ( measure echocardiogram MUGA scan ) . Normal organ marrow function define : ( leukocytes &gt; =3000/mcL ; absolute neutrophil count &gt; =1,500/mcL ; platelet &gt; =100,000/mcL ; total bilirubin within 1.25 x normal institutional limit ( exception Gilbert 's syndrome ) ; AST ( SGOT ) /ALT ( SGPT ) within 1.25 x institutional upper limit normal creatinine within normal institutional limit Availability tumor tissue suitable biological molecular examination start primary treatment Ability understand willingness sign write informed consent document Stage IIIB , IIIC , inflammatory breast cancer Stage IV breast cancer Prior treatment chemotherapy , endocrine therapy radiotherapy . Prior treatment HER2 target therapy LVEF ULN Uncontrolled hypertension ( systolic &gt; 150 mm Hg and/or diastolic &gt; 100 mm Hg ) clinically significant ( i.e . active ) cardiovascular disease : cerebrovascular accident ( CVA ) /stroke myocardial infarction within 6 month prior first study medication , unstable angina , congestive heart failure ( CHF ) New York Heart Association ( NYHA ) grade II high , serious cardiac arrhythmia require medication . Received investigational treatment within 4 week study start . Subjects know infection HIV , HBV , HCV Known hypersensitivity study drug excipients . Dyspnoea rest disease require continuous oxygen therapy . Psychiatric illness/social situation would limit compliance study requirement Subjects assess investigator unable unwilling comply requirement protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>HER2+/HR+</keyword>
	<keyword>breast cancer</keyword>
</DOC>